Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of JNJ-42756493 in Advanced or Refractory Solid Tumors or Lymphoma
jRCT2080223021Phase 1
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of erdafitinib in Nonhematologic neoplasms, lymphoma, gastric adenocarcinoma and 1 more, sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and tolerability of JNJ-42756493, Pharmacokinetics of JNJ-42756493 and 1 more.
02
Drugs
erdafitinib
03
Conditions
Nonhematologic neoplasmslymphomagastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080223021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223021.